LOPRESSOR HCT Drug Patent Profile
✉ Email this page to a colleague
When do Lopressor Hct patents expire, and what generic alternatives are available?
Lopressor Hct is a drug marketed by Validus Pharms and is included in one NDA.
The generic ingredient in LOPRESSOR HCT is hydrochlorothiazide; metoprolol tartrate. There are thirty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; metoprolol tartrate profile page.
Summary for LOPRESSOR HCT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 135 |
| Clinical Trials: | 26 |
| Patent Applications: | 3,802 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for LOPRESSOR HCT |
| What excipients (inactive ingredients) are in LOPRESSOR HCT? | LOPRESSOR HCT excipients list |
| DailyMed Link: | LOPRESSOR HCT at DailyMed |
Recent Clinical Trials for LOPRESSOR HCT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Center for Advancing Translational Science (NCATS) | Phase 2 |
| University of Wisconsin, Madison | Phase 2 |
| Corcept Therapeutics | Phase 1 |
Pharmacology for LOPRESSOR HCT
| Drug Class | Thiazide Diuretic beta-Adrenergic Blocker |
| Mechanism of Action | Adrenergic beta-Antagonists |
| Physiological Effect | Increased Diuresis |
Anatomical Therapeutic Chemical (ATC) Classes for LOPRESSOR HCT
US Patents and Regulatory Information for LOPRESSOR HCT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Validus Pharms | LOPRESSOR HCT | hydrochlorothiazide; metoprolol tartrate | TABLET;ORAL | 018303-001 | Dec 31, 1984 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Validus Pharms | LOPRESSOR HCT | hydrochlorothiazide; metoprolol tartrate | TABLET;ORAL | 018303-002 | Dec 31, 1984 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Validus Pharms | LOPRESSOR HCT | hydrochlorothiazide; metoprolol tartrate | TABLET;ORAL | 018303-003 | Dec 31, 1984 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LOPRESSOR HCT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Validus Pharms | LOPRESSOR HCT | hydrochlorothiazide; metoprolol tartrate | TABLET;ORAL | 018303-003 | Dec 31, 1984 | ⤷ Try a Trial | ⤷ Try a Trial |
| Validus Pharms | LOPRESSOR HCT | hydrochlorothiazide; metoprolol tartrate | TABLET;ORAL | 018303-002 | Dec 31, 1984 | ⤷ Try a Trial | ⤷ Try a Trial |
| Validus Pharms | LOPRESSOR HCT | hydrochlorothiazide; metoprolol tartrate | TABLET;ORAL | 018303-001 | Dec 31, 1984 | ⤷ Try a Trial | ⤷ Try a Trial |
| Validus Pharms | LOPRESSOR HCT | hydrochlorothiazide; metoprolol tartrate | TABLET;ORAL | 018303-002 | Dec 31, 1984 | ⤷ Try a Trial | ⤷ Try a Trial |
| Validus Pharms | LOPRESSOR HCT | hydrochlorothiazide; metoprolol tartrate | TABLET;ORAL | 018303-003 | Dec 31, 1984 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for LOPRESSOR HCT
See the table below for patents covering LOPRESSOR HCT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| France | 2081523 | ⤷ Try a Trial | |
| Switzerland | 563339 | ⤷ Try a Trial | |
| Canada | 982140 | PHENOXY-HYDROXYPROPYLAMINES AND THEIR PREPARATION | ⤷ Try a Trial |
| Austria | 317181 | ⤷ Try a Trial | |
| United Kingdom | 1308106 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LOPRESSOR HCT
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0565634 | 06C0030 | France | ⤷ Try a Trial | PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607 |
| 0454511 | 99C0009 | Belgium | ⤷ Try a Trial | PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015 |
| 0503785 | CA 2011 00026 | Denmark | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216 |
| 0454511 | SPC/GB99/008 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015 |
| 0502314 | SPC/GB02/037 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
